GSK (LON:GSK – Get Rating)‘s stock had its “hold” rating reissued by research analysts at Deutsche Bank Aktiengesellschaft in a research report issued to clients and investors on Wednesday, Marketbeat reports. They presently have a GBX 1,500 ($17.63) price objective on the stock. Deutsche Bank Aktiengesellschaft’s target price would suggest a potential upside of 10.75% from the stock’s previous close.
A number of other equities research analysts have also recently commented on GSK. Berenberg Bank lowered their price objective on shares of GSK from GBX 1,950 ($22.91) to GBX 1,580 ($18.57) and set a “buy” rating on the stock in a research note on Wednesday, September 14th. Shore Capital reissued a “buy” rating on shares of GSK in a research note on Wednesday, November 2nd. JPMorgan Chase & Co. lowered their price objective on shares of GSK from GBX 1,900 ($22.33) to GBX 1,600 ($18.80) and set a “neutral” rating on the stock in a research note on Tuesday, November 8th. Citigroup reissued a “neutral” rating and issued a GBX 1,975 ($23.21) price objective on shares of GSK in a research note on Thursday, July 21st. Finally, UBS Group set a GBX 1,300 ($15.28) price target on shares of GSK in a research note on Friday, November 11th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of GBX 1,622 ($19.06).
GSK Price Performance
Shares of LON GSK opened at GBX 1,354.40 ($15.92) on Wednesday. The stock has a market cap of £55.09 billion and a price-to-earnings ratio of 1,242.57. GSK has a 52 week low of GBX 1,280.92 ($15.05) and a 52 week high of GBX 1,824.40 ($21.44). The company’s 50-day moving average price is GBX 1,360.30 and its 200 day moving average price is GBX 1,553.04. The company has a current ratio of 0.97, a quick ratio of 0.73 and a debt-to-equity ratio of 253.74.
Insider Buying and Selling
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.